Cardiovascular risk assessment in children with chronic kidney disease

Rukshana Shroff, Arianna Dégi, Andrea Kerti, Éva Kis, Orsolya Cseprekál, K. Tory, Attila J. Szabó, G. Reusz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is a major factor contributing to cardiovascular (CV) morbidity and mortality with the highest risk in patients on dialysis. An estimation of CV risk is important not only to identify potential modifiable risk factors but also to evaluate the effect of treatments aimed to reduce the risk. Non-invasive methods of measuring vascular changes and circulating biomarkers are available to assess the presence and severity of cardiovascular damage. These include measures of structural (carotid intima-media thickness and coronary artery calcification score) and functional (aortic pulse wave velocity, 24-h ambulatory blood pressure monitoring, ambulatory arterial stiffness index, heart rate variability and flow-mediated dilatation) changes in the vessel wall. In addition, a number of circulating biomarkers of vascular damage and its progression have been studied. Many of these tests are well validated as surrogate markers of future cardiovascular events and death in adult CKD patients, but need technical adaptation, standardization and validation for use in children. With our current state of knowledge, these are best reserved for research studies and scarce clinical resources may be better utilized for preventative strategies to reduce the modifiable risk factors for calcification from early CKD stages.

Original languageEnglish
Pages (from-to)875-884
Number of pages10
JournalPediatric Nephrology
Volume28
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Chronic Renal Insufficiency
Biomarkers
Blood Vessels
Carotid Intima-Media Thickness
Ambulatory Blood Pressure Monitoring
Pulse Wave Analysis
Vascular Stiffness
Dilatation
Dialysis
Coronary Vessels
Heart Rate
Morbidity
Mortality
Research
Therapeutics

Keywords

  • Biomarkers
  • Cardiovascular disease
  • Carotid intima-media thickness
  • Chronic kidney disease
  • Pulse wave velocity

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Cardiovascular risk assessment in children with chronic kidney disease. / Shroff, Rukshana; Dégi, Arianna; Kerti, Andrea; Kis, Éva; Cseprekál, Orsolya; Tory, K.; Szabó, Attila J.; Reusz, G.

In: Pediatric Nephrology, Vol. 28, No. 6, 06.2013, p. 875-884.

Research output: Contribution to journalArticle

Shroff, R, Dégi, A, Kerti, A, Kis, É, Cseprekál, O, Tory, K, Szabó, AJ & Reusz, G 2013, 'Cardiovascular risk assessment in children with chronic kidney disease', Pediatric Nephrology, vol. 28, no. 6, pp. 875-884. https://doi.org/10.1007/s00467-012-2325-3
Shroff, Rukshana ; Dégi, Arianna ; Kerti, Andrea ; Kis, Éva ; Cseprekál, Orsolya ; Tory, K. ; Szabó, Attila J. ; Reusz, G. / Cardiovascular risk assessment in children with chronic kidney disease. In: Pediatric Nephrology. 2013 ; Vol. 28, No. 6. pp. 875-884.
@article{475c02700f094abfb43af59ff3661d04,
title = "Cardiovascular risk assessment in children with chronic kidney disease",
abstract = "Chronic kidney disease (CKD) is a major factor contributing to cardiovascular (CV) morbidity and mortality with the highest risk in patients on dialysis. An estimation of CV risk is important not only to identify potential modifiable risk factors but also to evaluate the effect of treatments aimed to reduce the risk. Non-invasive methods of measuring vascular changes and circulating biomarkers are available to assess the presence and severity of cardiovascular damage. These include measures of structural (carotid intima-media thickness and coronary artery calcification score) and functional (aortic pulse wave velocity, 24-h ambulatory blood pressure monitoring, ambulatory arterial stiffness index, heart rate variability and flow-mediated dilatation) changes in the vessel wall. In addition, a number of circulating biomarkers of vascular damage and its progression have been studied. Many of these tests are well validated as surrogate markers of future cardiovascular events and death in adult CKD patients, but need technical adaptation, standardization and validation for use in children. With our current state of knowledge, these are best reserved for research studies and scarce clinical resources may be better utilized for preventative strategies to reduce the modifiable risk factors for calcification from early CKD stages.",
keywords = "Biomarkers, Cardiovascular disease, Carotid intima-media thickness, Chronic kidney disease, Pulse wave velocity",
author = "Rukshana Shroff and Arianna D{\'e}gi and Andrea Kerti and {\'E}va Kis and Orsolya Cseprek{\'a}l and K. Tory and Szab{\'o}, {Attila J.} and G. Reusz",
year = "2013",
month = "6",
doi = "10.1007/s00467-012-2325-3",
language = "English",
volume = "28",
pages = "875--884",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Cardiovascular risk assessment in children with chronic kidney disease

AU - Shroff, Rukshana

AU - Dégi, Arianna

AU - Kerti, Andrea

AU - Kis, Éva

AU - Cseprekál, Orsolya

AU - Tory, K.

AU - Szabó, Attila J.

AU - Reusz, G.

PY - 2013/6

Y1 - 2013/6

N2 - Chronic kidney disease (CKD) is a major factor contributing to cardiovascular (CV) morbidity and mortality with the highest risk in patients on dialysis. An estimation of CV risk is important not only to identify potential modifiable risk factors but also to evaluate the effect of treatments aimed to reduce the risk. Non-invasive methods of measuring vascular changes and circulating biomarkers are available to assess the presence and severity of cardiovascular damage. These include measures of structural (carotid intima-media thickness and coronary artery calcification score) and functional (aortic pulse wave velocity, 24-h ambulatory blood pressure monitoring, ambulatory arterial stiffness index, heart rate variability and flow-mediated dilatation) changes in the vessel wall. In addition, a number of circulating biomarkers of vascular damage and its progression have been studied. Many of these tests are well validated as surrogate markers of future cardiovascular events and death in adult CKD patients, but need technical adaptation, standardization and validation for use in children. With our current state of knowledge, these are best reserved for research studies and scarce clinical resources may be better utilized for preventative strategies to reduce the modifiable risk factors for calcification from early CKD stages.

AB - Chronic kidney disease (CKD) is a major factor contributing to cardiovascular (CV) morbidity and mortality with the highest risk in patients on dialysis. An estimation of CV risk is important not only to identify potential modifiable risk factors but also to evaluate the effect of treatments aimed to reduce the risk. Non-invasive methods of measuring vascular changes and circulating biomarkers are available to assess the presence and severity of cardiovascular damage. These include measures of structural (carotid intima-media thickness and coronary artery calcification score) and functional (aortic pulse wave velocity, 24-h ambulatory blood pressure monitoring, ambulatory arterial stiffness index, heart rate variability and flow-mediated dilatation) changes in the vessel wall. In addition, a number of circulating biomarkers of vascular damage and its progression have been studied. Many of these tests are well validated as surrogate markers of future cardiovascular events and death in adult CKD patients, but need technical adaptation, standardization and validation for use in children. With our current state of knowledge, these are best reserved for research studies and scarce clinical resources may be better utilized for preventative strategies to reduce the modifiable risk factors for calcification from early CKD stages.

KW - Biomarkers

KW - Cardiovascular disease

KW - Carotid intima-media thickness

KW - Chronic kidney disease

KW - Pulse wave velocity

UR - http://www.scopus.com/inward/record.url?scp=84880571836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880571836&partnerID=8YFLogxK

U2 - 10.1007/s00467-012-2325-3

DO - 10.1007/s00467-012-2325-3

M3 - Article

VL - 28

SP - 875

EP - 884

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 6

ER -